Cytokinetics Inc. Stock
Cytokinetics Inc. Stock
There is an upward development for Cytokinetics Inc. compared to yesterday, with an increase of €1.00 (1.720%).
With 39 Buy predictions and not a single Sell prediction Cytokinetics Inc. is an absolute favorite of our community.
With a target price of 72 € there is a positive potential of 21.01% for Cytokinetics Inc. compared to the current price of 59.5 €.
So far the community has only identified positive things for Cytokinetics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | 1.720% | 5.310% | 10.185% | 23.444% | 11.215% | 43.720% | 247.953% |
| Biocryst Pharmaceuticals | -0.120% | 10.239% | 12.387% | -18.207% | -1.464% | -25.162% | -33.512% |
| Heron Therapeutics Inc. | -10.110% | -7.850% | -25.626% | -45.666% | -17.280% | -57.269% | -93.736% |
| Madrigal Pharmaceuticals inc. | -0.810% | -9.044% | -8.016% | 21.382% | -24.955% | 42.786% | 270.213% |
Comments
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Royal Bank Of Canada from $95.00 to $101.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
News
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly